US2005171081A1PendingUtilityA1
Imidazole alkaloids from lepidium meyenii and methods of usage
Est. expiryAug 14, 2022(expired)· nominal 20-yr term from priority
A61P 35/00C07D 233/58
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to novel imidazole alkaloid compounds that have been isolated as a form of chloride salt from a root extract of Lepidium meyenii Walp, with the common name Maca, and identified below as 1,3-bis(phenylmethyl)-4,5-dimethyl-1H-imidazlium chloride and 1,3-bis(phenylmethyl)-2,4,5-trimethyl-1H-imidazlium chloride, compounds (1) and (2), respectively. The present invention further relates to the use of these novel compounds (1) and (2) to treat proliferative diseases, such as but not limited to cancer.
Claims
exact text as granted — not AI-modified1 . The compound of claim 3 having the formula:
2 . The compound of claim 3 having the formula:
3 . A compound having the formula:
wherein R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are hydrogen, hydroxyl, methyl, methoxyl, aldehyde, COOH, NO 2 , NH 2 groups, or combinations thereof.
4 .- 9 . (canceled)
10 . A method of treating a proliferative disease, which comprises administering to a patient suffering from said proliferative disease a compound having the formula:
wherein R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are hydrogen, hydroxyl, methyl, methoxyl, aldehyde, COOH, NO 2 , NH 2 groups, or combinations thereof.
11 . The method according to claim 10 , wherein said proliferative disease is cancer.
12 . The method according to claim 10 wherein said cancer is selected from the group comprising: lung carcinoma; bladder carcinoma; colon adenocarcinoma; prostate adenocarcinoma; pancreatic adenocarcinoma; kidney carcinoma; breast carcinoma; ovarian carcinoma.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.